This compares to an ORR of 61% and 70% in patients with RET fusion–positive NSCLC who received prior platinum therapy and no prior systemic treatment, respectively, and an ORR of 89% for patients with RET fusion–positive thyroid cancer in previously published data on the ARROW study10,11. Here, RET is linked to thyroid gland carcinoma.